Use: Labeled indications
- To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
- For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older.
Full indications and usage US FDA label
1. INDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. (1.1) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older.
(1.2) 1.1 Heart Failure in Adult Patients Corlanor is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. 1.2 Heart Failure in Pediatric Patients Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.
Contraindications
4. CONTRAINDICATIONS Corlanor is contraindicated in patients with:
- Acute decompensated heart failure
- Clinically significant hypotension
- Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present
- Clinically significant bradycardia [see Warnings and Precautions (5.3)]
- Severe hepatic impairment [see Use in Specific Populations (8.6)]
- Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3)]
- Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1)] Acute decompensated heart failure (4) Clinically significant hypotension (4) Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present (4) Clinically significant bradycardia (4) Severe hepatic impairment (4) Heart rate maintained exclusively by the pacemaker (4) In combination with strong cytochrome CYP3A4 inhibitors (4)
Dosing: Adult
- 2. DOSAGE AND ADMINIST R ATION Adult and pediatric patients greater than 40 kg Starting dose is 2.5 (pediatrics and vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. (2.1)
- Pediatric patients less than 40 kg Starting dose is 0.05 mg/kg twice daily with food. Adjust dose at two-week intervals by 0.05 mg/kg based on heart rate. Maximum dose is 0.2 mg/kg (patients 6 months to less than 1 year old) or 0.3 mg/kg (patients 1 year old and older), up to a total of 7.5 mg twice daily.
2.1 Adults
2.1 Adults The recommended starting dose of Corlanor is 5 mg twice daily with food. Assess patient after two weeks and adjust dose to achieve a resting heart rate between 50 and 60 beats per minute (bpm) as shown in Table 1. Thereafter, adjust dose as needed based on resting heart rate and tolerability. The maximum dose is 7.5 mg twice daily.
In adult patients unable to swallow tablets, Corlanor oral solution can be used [see Clinical Pharmacology (12.3)]. In patients with a history of conduction defects or other patients in whom bradycardia could lead to hemodynamic compromise, initiate therapy at 2.5 mg twice daily before increasing the dose based on heart rate [see Warnings and Precautions (5.3)].
Table 1. Dose Adjustment for Adults Heart Rate Dose Adjustment > 60 bpm Increase dose by 2.5 mg (given twice daily) up to a maximum dose of 7.5 mg twice daily 50-60 bpm Maintain dose < 50 bpm or signs and symptoms of bradycardia Decrease dose by 2.5 mg (given twice daily); if current dose is 2.5 mg twice daily, discontinue therapy* * [see Warnings and Precautions (5.3)]
2.2 Pediatric Patients Recommended Dosage
2.2 Pediatric Patients Recommended Dosage Pediatric Patients 6 Months of Age and Older Weighing Less than 40 kg (Oral Solution) The recommended starting dose of Corlanor oral solution in pediatric patients 6 months of age and older and weighing less than 40 kg is 0.05 mg/kg twice daily with food. Assess patient at two-week intervals and adjust dose by 0.05 mg/kg to target a heart rate (HR) reduction of at least 20%, based on tolerability.
The maximum dose is 0.2 mg/kg twice daily for patients 6 months to less than 1 year old, and 0.3 mg/kg twice daily for patients 1 year old and older, up to a total of 7.5 mg twice daily. If a dose of Corlanor is missed or spit out, do not give another dose to make up for the missed or spit out dose. Give the next dose at the usual time.
Pediatric Patients Weighing 40 kg and Greater (Tablets) The recommended starting dose of Corlanor tablets in pediatric patients weighing more than 40 kg is 2.5 mg twice daily with food. Assess patient at two-week intervals and adjust dose by 2.5 mg to target a heart rate (HR) reduction of at least 20%, based on tolerability.
The maximum dose is 7.5 mg twice daily. In patients unable to swallow tablets, Corlanor oral solution can be used. Dose Reduction for Bradycardia If bradycardia develops, reduce the dose to the previous titration step. In patients who develop bradycardia at the recommended initial dosage, consider reducing the dosage to 0.02 mg/kg twice daily.
Oral Solution Preparation and Administration To administer Corlanor oral solution, empty the entire contents of the ampule(s) into a medication cup. With a calibrated oral syringe, measure the prescribed dose of Corlanor from the medication cup and administer the drug orally. Corlanor oral solution is sterile and preservative-free.
Discard the unused oral solution. Do not store or reuse any oral solution left in either the medication cup or an ampule.
Dosing: Altered kidney function
8.7 Renal Impairment No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min. No data are available for patients with creatinine clearance below 15 mL/min [see Clinical Pharmacology (12.3)].
Renal Impairment Renal impairment (creatinine clearance from 15 to 60 mL/min) has minimal effect on the pharmacokinetics of Corlanor. No data are available for patients with creatinine clearance below 15 mL/min.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. Corlanor is contraindicated in patients with severe hepatic impairment (Child-Pugh C) as it has not been studied in this population and an increase in systemic exposure is anticipated [see Contraindications (4) and Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of Corlanor have been established in pediatric patients (age 6 months to less than 18 years old) and are supported by pharmacokinetic and pharmacodynamic trials and evidence from adequate and well-controlled trials of Corlanor in adult patients. The pediatric study included 116 patients in the following age groups: 17 patients in the 6 months to less than 12 months age group, 36 patients in the 1 year to less than 3 years age group, and 63 patients in the 3 years to less than 18 years age group [see Dosage and Administration (2.2), Adverse Reactions (6.1), Clinical Pharmacology (12.3) and Clinical Studies (14.2)].
The safety and efficacy of Corlanor have not been established in patients less than 6 months of age. Animal Data Ivabradine given orally to juvenile rats from post-natal day (PND) 7 until PND 77 at 7.5, 15 and 30 mg/kg/day did not affect post-natal (pre-weaning) development and reproductive performance (post-weaning development).
Similar to adult animals, ivabradine decreased heart rate dose-dependently, and increased heart weights at the highest dose administered. Ivabradine also decreased white blood cell counts (lymphocytes) at the highest dose administered. The decrease in white blood cell counts partially reversed within a 3-week recovery period.
Exposures in male and female rats at the No Observed Adverse Effect Level (NOAEL) of 7.5 mg/kg/day, was approximately 3 and 8 times, respectively, steady state exposure associated with the highest received maintenance doses across age groups in pediatric patients (based on AUCs).
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use No pharmacokinetic differences have been observed in elderly (≥ 65 years) or very elderly (≥ 75 years) patients compared to the overall population. However, Corlanor has only been studied in a limited number of patients ≥ 75 years of age.
Dosage forms
Philippines
- Film-coated tablet: 5 mg, 7.5 mg
Registered products in the Philippines
46 products registered with the Food and Drug Administration (FDA) Philippines list Ivabradine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products46
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AbrinIvabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The Searle Company LimitedPakistan | Getz Bros. Philippines, Inc. | DR-XY49087 | May 21, 2029 | |
AldricardIvabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: Innogen Pharmaceuticals, Inc. | DR-XY47513 | Nov 17, 2031 | |
AldricardIvabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: Innogen Pharmaceuticals, Inc. | DR-XY47449 | Oct 14, 2036 | |
Bivelen 7.5Ivabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu-PVC/PE/PVDC/Blister Pack x 14's (Box of 56's) | RxVAT-exempt | Delorbis Pharmaceuticals Ltd.Cyprus | Healol Pharma Corporation | DRP-18875 | Sep 16, 2031 | |
BradikonIvabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-18967 | Oct 8, 2031 | |
BradipectIvabradine (as hydrochloride) | 5 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | October Pharma S.A.E.Egypt | Stangen Pharmaceuticals Philippines Inc. | DRP-16409 | Mar 10, 2028 | |
BradiremIvabradine Hydrochloride | 5 mg Film-Coated TabletAluminum-OPA/Alu/PVC Blister Pack x 14's (Box of 56's) | RxVAT-exempt | Remedia Ltd.Cyprus | Ambica International CorporationTrader: N/A | DRP-13457 | Feb 22, 2028 | |
BradiremIvabradine Hydrochloride | 7.5 mg Film-Coated TabletAluminum-OPA/Alu/PVC Blister Pack x 14's [Box of 56's) | RxVAT-exempt | Remedica Ltd.Cyprus | Ambica International Corporation.Importer: Ambica International Corporation | DRP-13456 | Feb 22, 2028 | |
BradisynIvabradine (as hydrochloride) | 5mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Synmosa Biopharma Philippines Inc.Importer: Medethix, Inc. | DRP-12767-02 | Oct 5, 2027 | |
BradisynIvabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu / Clear PVC Blister Pack of 14's (Box of 28's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Synmosa Biopharma Philippines Inc.Importer: MedEthix, Inc. | DRP-6523-04 | Feb 3, 2031 | |
BravadineIvabradine (as hydrochloride) | 7.5mg Film-Coated TabletAlu/Clear PVC Blister Pack of 14's (Box of 28's) | RxVAT-exempt | Bafna Pharmaceuticals Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-6523-02 | Nov 19, 2031 | |
CoralanIvabradine (as hydrochloride) | 5 mg Film-Coated TabletPVC/ Alu Blister Pack x 14's (Box of 56's) | RxVAT-exempt | Les Laboratoires Servier IndustrieFrance | Zuellig Pharma CorporationImporter: Servier Philippines, Inc. | DR-XY32013 | May 26, 2031 | |
CoralanIvabradine (as hydrochloride) | 7.5 mgPVC/ Alu Blister Pack x 14's (Box of 56's) | RxVAT-exempt | Les Laboratoires Servier IndustrieFrance | Zuellig Pharma CorporationImporter: Servier Philippines, Inc. | DR-XY32012 | May 26, 2031 | |
Decatrol 5Ivabradine Hydrochloride | 5 MG Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's, 60's and 100's) | RxVAT-exempt | Healthcare Pharmaceuticals LimitedBangladesh | Despina Pharma Inc. | DRP-18923 | Sep 30, 2031 | |
Decatrol 7.5Ivabradine Hydrochloride | 7.5 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's, 60's and 100's) | RxVAT-exempt | Healthcare Pharmaceuticals LimitedBangladesh | Despina Pharma Inc.Trader: N/A | DRP-18924 | Sep 30, 2031 | |
GardaIvabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY48973 | Jan 4, 2029 | |
GardaIvabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY48972 | Jan 4, 2029 | |
GavrilaIvabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Corbridge Group Phils.,Inc.Importer: Medethix Inc. | DRP-16393-01 | Feb 26, 2030 | |
GavrilaIvabradine (as hydrochloride) | 5mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Corbridge Group Phils., Inc.Importer: Medethix Inc. | DRP-12767-01 | Oct 5, 2027 | |
GavrilaIvabradine (as hydrochloride) | 7.5mg Film-Coated TabletAlu/Clear PVC Blister Pack of 14's (Box of 28's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Corbridge Group Phils., Inc.Importer: Medethix Inc. | DRP-6523-03 | Oct 29, 2031 | |
IadinIvabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu Blister Pack x 14's (Box of 28's and Box of 56's) | RxVAT-exempt | Laboratorios Liconsa, S.A.Spain | The Cathay YSS Distributors Co., Inc. | DR-XY49451 | Jul 15, 2030 | |
Ibdzine 7.5Ivabradine (as hydrochloride) | 7.5mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Centaur Pharmaceuticals Private LimitedIndia | Healol Pharma Corporation | DRP-17006 | Sep 5, 2030 | |
IbraIvabradine (as hydrochloride) | 5mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc. | DR-XY47455 | Oct 12, 2031 | |
IbracorIvabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc. | DR-XY48829 | Aug 1, 2028 | |
IVABIvabradine (as hydrochloride) | 7.5mg Film- Coated TabletAlu/Clear PVC Blister Pack of 14's (Box of 28's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Medethix, Inc. | DRP-6523 | Feb 3, 2031 | |
Ivab-5Ivabradine (as hydrochloride) | 5mg Film-Coated TabletAlu/Clear PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | MedEthix, Inc. | DRP-16393 | Feb 26, 2030 | |
IvacoreIvabradine (as hydrochloride) | 5 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15111 | May 2, 2029 | |
IvacoreIvabradine (as hydrochloride) | 5 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) ck x 10's (Box of 30's) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15368 | Jun 27, 2029 | |
IvacoreIvabradine (as hydrochloride) | 7.5 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15369 | Jun 27, 2029 | |
IvacoreIvabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15112 | May 2, 2029 | |
IvaheartIvabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu-PTP/PVDC/PVC Blister Pack x 14's (Box of 56's) | RxVAT-exempt | Standard Chem. & Pharm. Co., Ltd. (Plant II)Taiwan | Standard Chem & Pharm. Philippines. Inc. | DRP-17025 | Sep 9, 2030 | |
Ivapro 5Ivabradine | 5 mg Film-Coated TabletAlu/Clear PVC blister pack x 7's (Box of 14's) | RxVAT-exempt | Medreich Limited (Unit 3)India | Despina Pharma Inc. | DRP-16436 | Mar 11, 2030 | |
Ivapro 7.5Ivabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 7's (Box of 14's) | RxVAT-exempt | Medreich Limited (Unit 3)India | Despina Pharma Inc. | DRP-16405 | Mar 4, 2030 | |
Ividin 5Ivabradine (as hydrochloride) | 5 mg Film-coated TabletAlu Dessicant-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Annora Pharma Private LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-16626 | May 21, 2030 | |
Ivra DIvabradine hydrochloride | 5 mg Film-Coated TabletAluminum-OPA/Alu/PVC Blister Pack x 14’s (Box of 56’s) | RxVAT-exempt | Remedica Ltd.Cyprus | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-13457-01 | Feb 22, 2028 | |
NoneIvabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Medethix, Inc. | DRP-12767 | Oct 5, 2032 | |
Siftus 5Ivabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu-PVC/PVDC Blister pack x 10's (Box of 30's); Alu-PVC/PVDC Blister pack x 10's (Box of 10's - Physician's sample) | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-9239 | Oct 20, 2030 | |
Siftus 5Ivabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu-Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc.Importer: Zydus Healthcare Philippines, Inc | DRP-9240 | Oct 20, 2037 | |
Siftus 7.5Ivabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu-PVC/PVDC Blister pack x 10's (Box of 30's); Alu-PVC/PVDC Blister pack x 10's (Box of 10's) - Physician's sample | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-9233 | Oct 20, 2030 | |
Siftus 7.5Ivabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-9238 | Oct 20, 2037 | |
SivabIvabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu/Alu Blister x 7's (Box of 28's); Alu/Alu Blister x 1's (Box of 1's) as Physician Sample | RxVAT-exempt | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DRP-12651 | Sep 30, 2030 | |
SivabIvabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Alu Blister x 7's (Box of 28's); Alu/Alu Blister x 1's (Box of 1's) as Physician Sample | RxVAT-exempt | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.) Inc. | DRP-12652 | Sep 30, 2030 | |
Toriva 5Ivabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY49315 | Jan 10, 2030 | |
Toriva 7.5Ivabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY49314 | Jan 10, 2030 | |
Valheart™Ivabradine (as hydrochloride) | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 56's) | RxVAT-exempt | Krka, D.D., Novo MestoSlovenia | Unilab, Inc. | DRP-11478 | Mar 15, 2027 | |
Valheart™Ivabradine (as hydrochloride) | 7.5 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 56's) | RxVAT-exempt | Krka, D.D., Novo MestoSlovenia | Unilab, Inc. | DRP-11477 | Mar 15, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3. DOSAGE FORMS AND STRENGT HS Corlanor Tablets 5 mg: salmon-colored, oval-shaped, film-coated tablet, functionally scored on both edges, debossed with “5” on one face and bisected on the other face. The tablet is scored and can be divided into equal halves to provide a 2.5 mg dose. 7.5 mg: salmon-colored, triangular-shaped, film-coated tablet debossed with “7.5” on one face and plain on the other face.
Corlanor Oral Solution Corlanor 5 mg/5 mL (1 mg/mL) oral solution is a colorless liquid in an opaque, plastic, ampule containing 5 mg of Corlanor in 5 mL of liquid. Tablets: 5 mg, 7.5 mg (3) Oral Solution: 5 mg/5 mL (1 mg/mL) (3)
Warnings/Precautions
- 5. WARNINGS AND PRECAUTIONS Fetal toxicity: Females should use effective contraception. (5.1)
- Monitor patients for atrial fibrillation. (5.2)
- Monitor heart rate decreases and bradycardia symptoms during treatment. (5.3)
- Not recommended in patients with 2 nd degree AV block. (5.3)
5.1 Fetal Toxicity
5.1 Fetal Toxicity Corlanor may cause fetal toxicity when administered to a pregnant woman based on findings in animal studies. Embryo-fetal toxicity and cardiac teratogenic effects were observed in fetuses of pregnant rats treated during organogenesis at exposures 1 to 3 times the human exposures (AUC 0-24hr) at the maximum recommended human dose (MRHD) [see Use in Specific Populations (8.1)].
Advise females of reproductive potential to use effective contraception when taking Corlanor [see Use in Specific Populations (8.3)].
5.2 Atrial Fibrillation
5.2 Atrial Fibrillation Corlanor increases the risk of atrial fibrillation. In the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT), the rate of atrial fibrillation was 5.0% per patient-year in patients treated with Corlanor and 3.9% per patient-year in patients treated with placebo [see Clinical Studies (14)].
Regularly monitor cardiac rhythm. Discontinue Corlanor if atrial fibrillation develops.
5.3 Bradycardia and Conduction Disturbances Adult Patients
5.3 Bradycardia and Conduction Disturbances Adult Patients Bradycardia, sinus arrest, and heart block have occurred with Corlanor. The rate of bradycardia was 6.0% per patient-year in patients treated with Corlanor (2.7% symptomatic; 3.4% asymptomatic) and 1.3% per patient-year in patients treated with placebo. Risk factors for bradycardia include sinus node dysfunction, conduction defects (e.g., 1 st or 2 nd degree atrioventricular block, bundle branch block), ventricular dyssynchrony, and use of other negative chronotropes (e.g., digoxin, diltiazem, verapamil, amiodarone).
Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions (6.2)]. Concurrent use of verapamil or diltiazem will increase Corlanor exposure, may themselves contribute to heart rate lowering, and should be avoided [see Clinical Pharmacology (12.3)].
Avoid use of Corlanor in patients with 2 nd degree atrioventricular block unless a functioning demand pacemaker is present [see Contraindications (4)]. Pediatric Patients Bradycardia and first-degree heart block were observed in pediatric patients treated with Corlanor. Asymptomatic and symptomatic bradycardia were observed in 6.8% and 4.1% of pediatric patients treated with Corlanor, respectively.
In the placebo treatment arm, 2.4% of pediatric patients had asymptomatic bradycardia, but none had symptomatic bradycardia. Bradycardia was managed through dose titration but did not result in study drug discontinuation [see Dosage and Administration (2.2)].
Drug interactions
- 7. DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. (7.1)
- Negative chronotropes increase risk of bradycardia; monitor heart rate. (7.2)
7.1 Cytochrome P450-Based Interactions
7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [s ee Contraindications (4) and Clinical Pharmacology (12.3)].
Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. Avoid concomitant use of moderate CYP3A4 inhibitors when using Corlanor. Examples of moderate CYP3A4 inhibitors include diltiazem, verapamil, and grapefruit juice [s ee Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
Avoid concomitant use of CYP3A4 inducers when using Corlanor. Examples of CYP3A4 inducers include St. John’s wort, rifampicin, barbiturates, and phenytoin [s ee Clinical Pharmacology (12.3)].
7.2 Negative Chronotropes
7.2 Negative Chronotropes Most patients receiving Corlanor will also be treated with a beta-blocker. The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking Corlanor with other negative chronotropes.
7.3 Pacemakers in Adults
7.3 Pacemakers in Adults Corlanor dosing is based on heart rate reduction, targeting a heart rate of 50 to 60 beats per minute in adults [see Dos ag e and Administration (2.1)]. Patients with demand pacemakers set to a rate ≥ 60 beats per minute cannot achieve a target heart rate < 60 beats per minute, and these patients were excluded from clinical trials [see Clinical Studies (14.1)].
The use of Corlanor is not recommended in patients with demand pacemakers set to rates ≥ 60 beats per minute.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Ivabradine is extensively metabolized in the liver and intestines by CYP3A4-mediated oxidation.
The N-desmethylated derivative is also metabolized by CYP3A4.
Drug Interactions The effects of coadministered drugs (CYP3A4 inhibitors, substrates, inducers, and other concomitantly administered drugs) on the pharmacokinetics of Corlanor were studied in several single- and multiple-dose studies.
Effect of Ivabradine on Metformin Pharmacokinetics Ivabradine, dosed at 10 mg twice daily to steady state, did not affect the pharmacokinetics of metformin (an organic cation transporter [OCT2] sensitive substrate).
DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers.
( 7.2 ) 7.1 Cytochrome P450-Based Interactions Corlanor is primarily metabolized by CYP3A4.
Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them.
The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )] .
Adverse reactions
6. ADVERSE REACTIONS Clinically significant adverse reactions that appear in other sections of the labeling include: Atrial Fibrillation [see Warnings and Precautions (5.2)] Bradycardia and Conduction Disturbances [see Warnings and Precautions (5.3)] Most common adverse reactions occurring in ≥ 1% of patients are bradycardia, hypertension, atrial fibrillation and luminous phenomena (phosphenes).
(6) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-772-6436 (1-800-77-AMGEN) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients with Heart Failure In SHIFT, safety was evaluated in 3,260 patients treated with Corlanor and 3,278 patients given placebo.
The median duration of Corlanor exposure was 21.5 months. The most common adverse drug reactions in the SHIFT trial are shown in Table 2 [see Warnings and Precautions (5.2), (5.3)]. Table 2. Adverse Drug Reactions with Rates ≥ 1.0% Higher on Ivabradine than Placebo occurring in > 1% on Ivabradine in SHIFT Ivabradine N = 3,260 Placebo N = 3,278 Bradycardia 10% 2.2% Hypertension, blood pressure increased 8.9% 7.8% Atrial fibrillation 8.3% 6.6% Phosphenes, visual brightness 2.8% 0.5% Luminous P henomena (Phosphenes) Phosphenes are phenomena described as a transiently enhanced brightness in a limited area of the visual field, halos, image decomposition (stroboscopic or kaleidoscopic effects), colored bright lights, or multiple images (retinal persistency).
Phosphenes are usually triggered by sudden variations in light intensity. Corlanor can cause phosphenes, thought to be mediated through Corlanor’s effects on retinal photoreceptors [see Clinical Ph a rmacology (12.1)]. Onset is generally within the first 2 months of treatment, after which they may occur repeatedly. Phosphenes were generally reported to be of mild to moderate intensity and led to treatment discontinuation in < 1% of patients; most resolved during or after treatment.
Pediatric Patients with Heart Failure The safety of Corlanor in pediatric patients 6 months to less than 18 years of age is based on a clinical trial [see Clinical Studies (14.2)] in symptomatic heart failure patients with dilated cardiomyopathy and elevated heart rate. This trial provides experience in 73 patients treated with Corlanor for a median duration of 397 days, and 42 patients given placebo.
Bradycardia (symptomatic and asymptomatic) occurred at rates similar to those in adults. Phosphenes were observed in pediatric patients treated with Corlanor.
6.2 Postmarketing Experience
6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure. The following adverse reactions have been identified in adults during post-approval use of Corlanor: syncope, hypotension, torsade de pointes, ventricular fibrillation, ventricular tachycardia, angioedema, erythema, rash, pruritus, urticaria, vertigo, and diplopia, and visual impairment.
Adverse reaction frequency tables (US label) US FDA label
| Ivabradine N = 3,260 | Placebo N = 3,278 | |
| Bradycardia | 10% | 2.2% |
| Hypertension, blood pressure increased | 8.9% | 7.8% |
| Atrial fibrillation | 8.3% | 6.6% |
| Phosphenes, visual brightness | 2.8% | 0.5% |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings in animals, Corlanor may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of Corlanor in pregnant women to inform any drug-associated risks. In animal reproduction studies, oral administration of ivabradine to pregnant rats during organogenesis at a dosage providing 1 to 3 times the human exposure (AUC 0-24hr) at the MRHD resulted in embryo-fetal toxicity and teratogenicity manifested as abnormal shape of the heart, interventricular septal defect, and complex anomalies of primary arteries.
Increased post-natal mortality was associated with these teratogenic effects in rats. In pregnant rabbits, increased post-implantation loss was noted at an exposure (AUC 0-24hr) 5 times the human exposure at the MRHD. Lower doses were not tested in rabbits. The background risk of major birth defects for the indicated population is unknown.
The estimated background risk of major birth defects in the U.S. general population is 2 to 4%, however, and the estimated risk of miscarriage is 15 to 20% in clinically recognized pregnancies. Advise a pregnant woman of the potential risk to the fetus. Clinical Considerations Disease-associated Maternal and/or Embryo - fetal Risk Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester.
Pregnant patients with left ventricular ejection fraction less than 35% on maximally tolerated doses of beta-blockers may be particularly heart rate dependent for augmenting cardiac output. Therefore, pregnant patients who are started on Corlanor, especially during the first trimester, should be followed closely for destabilization of their congestive heart failure that could result from heart rate slowing.
Monitor pregnant women with chronic heart failure in 3 rd trimester of pregnancy for preterm birth. Data Animal Data In pregnant rats, oral administration of ivabradine during the period of organogenesis (gestation day 6-15) at doses of 2.3, 4.6, 9.3, or 19 mg/kg/day resulted in fetal toxicity and teratogenic effects. Increased intrauterine and post-natal mortality and cardiac malformations were observed at doses ≥ 2.3 mg/kg/day (equivalent to the human exposure at the MRHD based on AUC 0- 24 hr).
Teratogenic effects including interventricular septal defect and complex anomalies of major arteries were observed at doses ≥ 4.6 mg/kg/day (approximately 3 times the human exposure at the MRHD based on AUC 0- 24 hr). In pregnant rabbits, oral administration of ivabradine during the period of organogenesis (gestation day 6-18) at doses of 7, 14, or 28 mg/kg/day resulted in fetal toxicity and teratogenicity.
Treatment with all doses ≥ 7 mg/kg/day (equivalent to the human exposure at the MRHD based on AUC 0- 24 hr) caused an increase in post-implantation loss. At the high dose of 28 mg/kg/day (approximately 15 times the human exposure at the MRHD based on AUC 0- 24 hr), reduced fetal and placental weights were observed, and evidence of teratogenicity (ectrodactylia observed in 2 of 148 fetuses from 2 of 18 litters) was demonstrated.
In the pre- and post-natal study, pregnant rats received oral administration of ivabradine at doses of 2.5, 7, or 20 mg/kg/day from gestation day 6 to lactation day 20. Increased post-natal mortality associated with cardiac teratogenic findings was observed in the F1 pups delivered by dams treated at the high dose (approximately 15 times the human exposure at the MRHD based on AUC 0- 24 hr).
Mechanism of action
12.1 Mechanism of Action Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial (SA) node, but prolongation of the AH interval has occurred as has PR interval prolongation.
There was no effect on ventricular repolarization and no effects on myocardial contractility [see Clinical Pharmacology (12.2)]. Corlanor can also inhibit the retinal current I h. I h is involved in curtailing retinal responses to bright light stimuli. Under triggering circumstances (e.g., rapid changes in luminosity), partial inhibition of I h by Corlanor may underlie the luminous phenomena experienced by patients.
Luminous phenomena (phosphenes) are described as a transient enhanced brightness in a limited area of the visual field [see A dverse R eactions (6.1)].
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Corlanor causes a dose-dependent reduction in heart rate. The size of the effect is dependent on the baseline heart rate (i.e., greater heart rate reduction occurs in patients with higher baseline heart rate). At recommended doses, heart rate reduction is approximately 10 bpm at rest and during exercise.
Analysis of heart rate reduction vs. dose indicates a plateau effect at doses > 20 mg twice daily. In a study of patients with preexisting conduction system disease (first- or second-degree AV block or left or right bundle branch block) requiring electrophysiologic study, IV ivabradine (0.20 mg/kg) administration slowed the overall heart rate by approximately 15 bpm, increased the PR interval (29 msec), and increased the AH interval (27 msec).
Corlanor does not have negative inotropic effects. Ivabradine increases the uncorrected QT interval with heart rate slowing but does not cause rate-corrected prolongation of QT.
Pharmacokinetics
Metabolism and Excretion The pharmacokinetics of ivabradine are linear over an oral dose range of 0.5 mg to 24 mg.
Ivabradine plasma levels decline with a distribution half-life of 2 hours and an effective half-life of approximately 6 hours.
The total clearance of ivabradine is 24 L/h, and renal clearance is approximately 4.2 L/h, with ~ 4% of an oral dose excreted unchanged in urine.
The excretion of metabolites occurs to a similar extent via feces and urine.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The peak concentration (C max) and area under the plasma concentration time curve (AUC) are similar for ivabradine and S 18982 between oral solution and tablets for the same dose. Absorption and B ioavailability Following oral administration, peak plasma ivabradine concentrations are reached in approximately 1 hour under fasting conditions.
The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver. Food delays absorption by approximately 1 hour and increases plasma exposure by 20% to 40%. Corlanor should be taken with food [see Dosage and Administration (2)]. Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L.
Metabolism and Excretion The pharmacokinetics of ivabradine are linear over an oral dose range of 0.5 mg to 24 mg. Ivabradine is extensively metabolized in the liver and intestines by CYP3A4-mediated oxidation. The major metabolite is the N-desmethylated derivative (S 18982), which is equipotent to ivabradine and circulates at concentrations approximately 40% that of ivabradine.
The N-desmethylated derivative is also metabolized by CYP3A4. Ivabradine plasma levels decline with a distribution half-life of 2 hours and an effective half-life of approximately 6 hours. The total clearance of ivabradine is 24 L/h, and renal clearance is approximately 4.2 L/h, with ~ 4% of an oral dose excreted unchanged in urine.
The excretion of metabolites occurs to a similar extent via feces and urine. Drug Interactions The effects of coadministered drugs (CYP3A4 inhibitors, substrates, inducers, and other concomitantly administered drugs) on the pharmacokinetics of Corlanor were studied in several single- and multiple-dose studies. Pharmacokinetic measures indicating the magnitude of these interactions are presented in Figure 2.
Figure 2. Impact of Co a dministered Drugs on the Pharmacokinetics of Corlanor Digoxin exposure did not change when concomitantly administered with ivabradine. No dose adjustment is required when ivabradine is concomitantly administered with digoxin. Effect of Ivabradine on Metformin Pharmacokinetics Ivabradine, dosed at 10 mg twice daily to steady state, did not affect the pharmacokinetics of metformin (an organic cation transporter [OCT2] sensitive substrate).
The geometric mean (90% confidence interval [CI]) ratios of C max and AUC inf of metformin, with and without ivabradine were 0.98 [0.83–1.15] and 1.02 [0.86–1.22], respectively. No dose adjustment is required for metformin when administered with Corlanor. Specific Populations Age No pharmacokinetic differences (AUC or C max) have been observed between elderly (≥ 65 years) or very elderly (≥ 75 years) patients and the overall patient population [see Use in Specific Populations (8.5)].
Hepatic Impairment In patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, the pharmacokinetics of Corlanor were similar to that in patients with normal hepatic function. No data are available in patients with severe hepatic impairment (Child-Pugh C) [see Contraindications (4)]. Renal Impairment Renal impairment (creatinine clearance from 15 to 60 mL/min) has minimal effect on the pharmacokinetics of Corlanor.
No data are available for patients with creatinine clearance below 15 mL/min. Pediatrics The pharmacokinetics of ivabradine and the major metabolite S 18982 were evaluated in 70 pediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years of age given ivabradine twice daily [see Clinical Studies (14.2)].
Ivabradine and S 18982 metabolite exposures were measured following weight-based dosing and dose titration designed to reach a dose that enables a 20% heart rate reduction without inducing bradycardia and/or signs or symptoms related to bradycardia. Analyses showed the relationship between exposure and heart rate reduction was similar across pediatric age groups and adults.
Steady state exposures of ivabradine and S 18982 following maintenance doses in pediatric patients are similar to exposures achieved in adult heart failure patients given 5 mg BID.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Corlanor · Amgen Inc [US FDA-approved label, version 36, November 9, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92018a65-38f6-45f7-91d4-a34921b81d0d
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .